[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C@H1][C@H1][Branch2][=Branch1][N][C@H1][Branch2][Branch1][S][C][C@@H1][Branch1][Ring2][O][Ring1][=Branch1][O][C@H1][C][C@@][Branch2][Ring2][=Branch2][C][C][=C][Ring1][=Branch1][C][=Branch2][Ring1][#C][=C][C][=Branch1][Branch1][=C][Ring1][=Branch1][O][C][=Branch1][C][=O][C][=C][Branch1][Branch1][C][Ring1][=Branch2][=O][C][=Branch1][=Branch1][=C][C][=C][Ring1][Branch2][O][C][O][Branch1][#Branch1][C][=Branch1][C][=O][C][O][O][N][C][C][O][C][C][Ring1][=Branch1][O]"}, {"from": "gpt", "value": "The molecule is a semisynthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin.  As an antineoplastic agent, morpholinodoxorubicin is more potent than doxorubicin.  Similar to doxorubicin, morpholinodoxorubicin intercalates into DNA and causes single- and double-strand breaks in DNA via inhibition of topoisomerase I and II.  Unlike doxorubicin, this agent is metabolized in vivo to a DNA-alkylating derivative that forms DNA interstrand cross-links, thereby potentiating its doxorubicin-like cytotoxicity. (NCI04)"}]